{"url_path":"/sec/aeon/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statement and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000052-index.html","accession_number":"0001837607-26-000052","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000052-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":200,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statement and Exhibits.**\n\n(d) Exhibits.\n\n​\n\n​\n\n**Exhibit No.**\n\n**Description**\n\n​\n\n​\n\n​\n\n1.1\n\n​\n\n[Underwriting Agreement, by and between the Company and Lake Street Capital Markets, LLC as representative of the several underwriters named herein, dated as of July 13, 2026.](aeon-20260713xex1d1.htm)\n\n4.1\n\n[Form of Pre-Funded Warrant.](aeon-20260713xex4d1.htm)\n\n4.2\n\n​\n\n[Form of Two-Year Milestone Warrant.](aeon-20260713xex4d2.htm)\n\n4.3\n\n​\n\n[Form of Five-Year Milestone Warrant.](aeon-20260713xex4d3.htm)\n\n4.4\n\n​\n\n[Warrant Agency Agreement, dated as of July 15, 2026, by and between AEON Biopharma, Inc. and Continental Stock Transfer & Trust Company, as warrant agent.](aeon-20260713xex4d4.htm)\n\n10.1\n\n​\n\n[Warrant Solicitation Agreement, dated as of July 13, 2026, by and among the Company, Lake Street Capital Markets, LLC and Laidlaw & Company (UK) Ltd.](aeon-20260713xex10d1.htm)\n\n99.1\n\n​\n\n[Press Release dated July 14, 2026.](aeon-20260713xex99d1.htm)\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**AEON Biopharma, Inc.**\n\nDate: July 15, 2026\n\nBy:\n\n/s/ Robert Bancroft\n\n​\n\n​\n\nRobert Bancroft\n\n​\n\n​\n\nChief Executive Officer\n\n​\n\n​\n\n​\n\n​"}